explore -WSS

explore

author：hotspot 2025-10-01 01:50:50 - browse：93

Paul Biondi Flagship

Pharma giant Pfizer is turning to venture firm Flagship for new drug development, signing a deal worth up to $7 billion to mine new medicines from the latter’s portfolio companies.

Flagship and Pfizer announced Tuesday that they will each put $50 million into developing up to 10 drug candidates. Pfizer will have first rights to acquire each for up to $700 million, plus royalties. Flagship’s portfolio companies will also share in any payments that come out of the partnership.

Flagship has historically developed new medicines by forming and spinning out startup companies, some of which have signed their own collaboration deals with the likes of Amgen or Nestlé Health Science. But in recent years, the firm has been pursuing external partnerships through a new business division called Pioneering Medicines, led by former Bristol Myers Squibb executive Paul Biondi. Pioneering Medicines uses technologies and other scientific platforms being developed by Flagship’s portfolio companies to look for possible therapies in disease areas that the startup may not be working in.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Clinical trials must include more disabled people

focus

knowledge

WSS

New details revealed about Purdue's marketing of OxyContin

Key House Republican on health care plans exit from Congress

BioAge raises $170M for combination therapy with Zepbound

The dental labor crisis is a moment of opportunity

Medicare Advantage proposed rates disappoint insurers

Hilary expected to bring catastrophic, life

explore

explore

entertainment

Guidelines to prevent youth baseball injuries need more muscle

Trump's false claims about Georgia's 2020 election long debunked

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Liz Cheney makes 1st public comment since Trump's election interference indictments

Medicare details structure of new drug price negotiation program

How digital tools helped lower hypertension in marginalized patients

Peter Hotez and the public health issue of online harassment

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Medical records are filled with copy

Eye stem cell transplant could help restore vision in injured people

focus

KalVista pill reduced swelling 'attacks' caused by genetic disease

PhRMA lawsuit over Medicare drug price negotiation tossed

What should King Charles tell the public about his cancer?

Industry veterans launch new biotech VC with $310M

Medicare Advantage proposed rates disappoint insurers

Evacuations in place as 3 wildfires burn in eastern Washington state

knowledge

focus

knowledge

leisure time